Aug 08, 2026 — Digital Edition
Gerald Ideas
Independent Journalism & Insight
Feature

Targeting Prostate Cancer The Tousled Way v2 - made for everyday living

Targeting Prostate Cancer, The 'Tousled Way' v2

Targeting Prostate Cancer The Tousled Way v2
Targeting Prostate Cancer The Tousled Way v2

Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas' associated with poor prognosis. Resistance to ADT arises through various mechanisms, and ...

Downregulation of mTOR by lentivirus inhibits prostate cancer cell
Downregulation of mTOR by lentivirus inhibits prostate cancer cell

Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis. Resistance to ADT arises through various mechanisms, and most ...

Targeting Prostate Cancer, the 'Tousled Way'

Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression

Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas …

Abstract Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis.

Stages of Prostate Cancer The Focal Therapy Clinic
Stages of Prostate Cancer The Focal Therapy Clinic

PDF Targeting Prostate Cancer, the Tousled Way

Abstract:Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treat- ment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis.

Abstract: Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and anti-androgens ...

Prostate cancer immunotherapy Improving clinical outcomes with a multi
Prostate cancer immunotherapy Improving clinical outcomes with a multi

Targeting Prostate Cancer, the 'Tousled Way'

Targeting TLK1 and its associated signaling could prevent PCa progression to the incurable metastatic castration-resistant PCa (mCRPC) stage and provide a promising approach to treating PCa. Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical ...

Review Targeting Prostate Cancer,The ' Tousled Way ' Siddhant Bhoir and Arrigo De Benedetti Department of Biochemistry and Molecular Biology, LSU Health Shreveport, LA 71103, USA C o ...

Why Are Prostate Cancer Preclinical Models Hard to Develop
Why Are Prostate Cancer Preclinical Models Hard to Develop

Targeting Prostate Cancer, the 'Tousled Way'.

Abstract Androgen deprivation therapy (ADT) has been the mainstay of prostate cancer (PCa) treatment, with success in developing more effective inhibitors of androgen synthesis and antiandrogens in clinical practice. However, hormone deprivation and AR ablation have caused an increase in ADT-insensitive PCas associated with a poor prognosis.

Prostate cancer initiation progression and metastasis to bone
Prostate cancer initiation progression and metastasis to bone
Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression
Pentamidine causes mtDNA reduction in prostate cancer cells A GSEA
Pentamidine causes mtDNA reduction in prostate cancer cells A GSEA
Prostate Cancer Signaling Pathway
Prostate Cancer Signaling Pathway
Frontiers
Frontiers
Figure 1 from Downregulation of CAMK2N1 due to DNA Hypermethylation
Figure 1 from Downregulation of CAMK2N1 due to DNA Hypermethylation
PDF Downregulation of γ Catenin by miR 195 5p Inhibits Colon Cancer
PDF Downregulation of γ Catenin by miR 195 5p Inhibits Colon Cancer
Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression
Downregulation of SEPTIN5 inhibits prostate cancer progression

Bhoir S, De Benedetti A. Targeting Prostate Cancer , the 'Tousled Way' . International Journal of Molecular Sciences. 2023; 24 (13):11100. https://doi.org/10.3390/ijms241311100